Patents by Inventor Bernard Christophe
Bernard Christophe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160367560Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.Type: ApplicationFiled: June 17, 2016Publication date: December 22, 2016Inventors: Anne Michel, Patrick Downey, Florian Montel, Dieter Scheller, Bernard Christophe
-
Publication number: 20160368920Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.Type: ApplicationFiled: July 22, 2016Publication date: December 22, 2016Applicant: AstraZeneca ABInventors: Bernard Christophe BARLAAM, Kurt Gordon PIKE
-
Publication number: 20160272607Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: ApplicationFiled: March 24, 2016Publication date: September 22, 2016Applicant: AstraZeneca ABInventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie, Paul LAMBERT-VAN DER BREMPT, Remy Robert MORGENTIN, Patrick PLE
-
Patent number: 9428503Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.Type: GrantFiled: May 5, 2015Date of Patent: August 30, 2016Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Kurt Gordon Pike
-
Patent number: 9387212Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.Type: GrantFiled: April 19, 2013Date of Patent: July 12, 2016Assignee: UCB Biopharma SPRLInventors: Anne Michel, Patrick Downey, Florian Montel, Dieter Scheller, Bernard Christophe
-
Publication number: 20160137634Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: August 31, 2015Publication date: May 19, 2016Applicant: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie, Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
-
Publication number: 20160060240Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: ApplicationFiled: April 8, 2015Publication date: March 3, 2016Applicant: ASTRAZENECA ABInventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie, Paul LAMBERT-VAN DER BREMPT, Remy Robert MORGENTIN, Patrick PLE
-
Publication number: 20150336952Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.Type: ApplicationFiled: May 5, 2015Publication date: November 26, 2015Applicant: ASTRAZENECA ABInventors: Bernard Christophe BARLAAM, Kurt Gordon PIKE
-
Patent number: 9156831Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 22, 2014Date of Patent: October 13, 2015Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Gilles Ouvry, Christine Marie Paul Lambert-Van Der Brempt, Craig Steven Harris, David Berry, Gary Peter Tomkinson, Gary Patrick Reid
-
Publication number: 20150157638Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.Type: ApplicationFiled: April 19, 2013Publication date: June 11, 2015Inventors: Anne Michel, Patrick Downey, Florian Montel, Dieter Scheller, Bernard Christophe
-
Patent number: 9029374Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: GrantFiled: January 24, 2014Date of Patent: May 12, 2015Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Sebastien Louis Degorce, Christine Marie Paul Lambert-Van Der Brempt, Remy Robert Morgentin, Patrick Ple
-
Publication number: 20140206700Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 22, 2014Publication date: July 24, 2014Applicant: ASTRAZENECA ABInventors: Bernard Christophe BARLAAM, Benedicte DELOUVRIE, Gilles OUVRY, Christine Marie, Paul, LAMBERT-VAN DER BREMPT, Craig Steven HARRIS, David BERRY, Gary Peter TOMKINSON, Gary Patrick REID
-
Publication number: 20140194419Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 24, 2014Publication date: July 10, 2014Applicant: AstraZeneca ABInventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie, Paul LAMBERT-VAN DER BREMPT, Remy Robert MORGENTIN, Patrick PLE
-
Patent number: 8673906Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: GrantFiled: February 13, 2013Date of Patent: March 18, 2014Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Sebastien Louis Degeorge, Christine Marie Paul Lambert-Van Der Brempt, Remy Robert Morgentin, Patrick Ple
-
Publication number: 20140038937Abstract: The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: ApplicationFiled: August 6, 2013Publication date: February 6, 2014Applicant: Astrazeneca ABInventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie Paul LAMBERT-VAN DER BREMPT, Jean-Jacques Marcel LOHMANN, Patrick PLE
-
Patent number: 8569298Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.Type: GrantFiled: June 15, 2009Date of Patent: October 29, 2013Assignee: Astrazeneca ABInventors: Bernard Christophe Barlaam, Patrick Ple, Kevin Michael Foote, Clifford David Jones
-
Patent number: 8530470Abstract: The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: GrantFiled: April 11, 2012Date of Patent: September 10, 2013Assignee: Astrazeneca ABInventors: Bernard Christophe Barlaam, Sebastien Louis Degorce, Christine Marie Paul Lambert-Van Der Brempt, Jean-Jacques Marcel Lohmann, Patrick Ple
-
Publication number: 20120329795Abstract: The invention concerns quinazoline derivatives of Formula I: wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.Type: ApplicationFiled: September 10, 2012Publication date: December 27, 2012Inventors: Laurent Francois Andre Hennequin, Bernard Christophe Barlaam, Robert Hugh Bradbury
-
Publication number: 20120264731Abstract: The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: ApplicationFiled: April 11, 2012Publication date: October 18, 2012Applicant: ASTRAZENECA ABInventors: Bernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie Paul LAMBERT-VAN DER BREMPT, Jean-Jacques Marcel LOHMANN, Patrick PLE
-
Publication number: 20110237610Abstract: The invention concerns quinazoline derivatives of Formula I wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.Type: ApplicationFiled: October 12, 2010Publication date: September 29, 2011Applicant: AstraZeneca ABInventors: Bernard Christophe Barlaam, Laurent Francois Andre Hennequin, Christopher Thomas Halsall